In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk
- PMID: 37665995
- DOI: 10.7326/J23-0069
In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk
Abstract
Loftus EV Jr, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023;388:1966-1980. 37224198.
Conflict of interest statement
Comment on
-
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.N Engl J Med. 2023 May 25;388(21):1966-1980. doi: 10.1056/NEJMoa2212728. N Engl J Med. 2023. PMID: 37224198 Clinical Trial.
Similar articles
-
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.N Engl J Med. 2023 May 25;388(21):1966-1980. doi: 10.1056/NEJMoa2212728. N Engl J Med. 2023. PMID: 37224198 Clinical Trial.
-
Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn's Disease.Inflamm Bowel Dis. 2023 Jul 5;29(7):1175-1176. doi: 10.1093/ibd/izad048. Inflamm Bowel Dis. 2023. PMID: 36933200
-
Upadacitinib therapy for Crohn's disease.Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):483. doi: 10.1038/s41575-023-00812-0. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37369736 No abstract available.
-
Systematic Review with Meta-analysis: Efficacy and Safety of Upadacitinib in Managing Moderate-to-Severe Crohn's Disease and Ulcerative Colitis.Clin Drug Investig. 2024 Jun;44(6):371-385. doi: 10.1007/s40261-024-01364-0. Epub 2024 May 23. Clin Drug Investig. 2024. PMID: 38777970
-
Upadacitinib in Crohn's disease.Expert Opin Pharmacother. 2024 Mar;25(4):359-370. doi: 10.1080/14656566.2024.2333964. Epub 2024 Mar 29. Expert Opin Pharmacother. 2024. PMID: 38512115 Review.
Cited by
-
The role of neutrophil extracellular traps in Crohn's disease.Heliyon. 2024 Nov 20;10(23):e40577. doi: 10.1016/j.heliyon.2024.e40577. eCollection 2024 Dec 15. Heliyon. 2024. PMID: 39654789 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical